Akers Presenting at US Investor Conference
February 05 2015 - 1:06PM
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the
"Company"), a medical device company focused on reducing the cost
of healthcare through faster, easier diagnosis, announces that its
Executive Chairman, Raymond F. Akers Jr., Ph.D, will present to
prospective investors next week at the
17th Annual
BIO CEO & Investor Conference in New York
City.
The BIO CEO & Investor Conference is one of the USA's
largest investor conferences focused on publicly traded and select
private biotech companies.
"I look forward to meeting prospective investors at the BIO CEO
conference next week and discussing how Akers is poised to
capitalize on the growth of the in vitro diagnostics market by
providing more rapid and easy diagnostic solutions to accelerate
clinical decision-making and reduce the cost of healthcare."
The 17th Annual BIO CEO & Investor
Conference is being held at the Waldorf Astoria New York
on February 9-10, 2015. For more information visit:
https://www.bio.org/events/conferences/bio-ceo-investor-conference.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products
can be found on our website at
www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, as amended. Such forward-looking statements reflect
the Company's expectations about its future operating results,
performance and opportunities that involve substantial risks and
uncertainties. These statements include but are not limited to
statements regarding the intended terms of the offering, closing of
the offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
RedChip Companies, Inc. (US Investor Relations)
Jon Cunningham
Tel. +1 407 644 4256 x107
Vigo Communications (UK Investor Relations)
Ben Simons/Alexandra Roper
Tel. +44 (0) 20 7016 9570
Email. akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024